Esperion Therapeutics, Inc. (ESPR)

$2.89

-0.01

(-0.34%)

Market is closed - opens 7 PM, 13 Jun 2024

Insights on Esperion Therapeutics, Inc.

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 32.25M → 137.73M (in $), with an average increase of 76.6% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -56.34M → 61.02M (in $), with an average increase of 192.3% per quarter

  • Vs NBIX

    In the last 3 years, Neurocrine Biosciences Inc. has given 35.0% return, outperforming this stock by 124.0%

Performance

  • $2.86
    $3.11
    $2.89
    downward going graph

    1.21%

    Downside

    Day's Volatility :8.05%

    Upside

    6.92%

    downward going graph
  • $0.70
    $3.40
    $2.89
    downward going graph

    75.78%

    Downside

    52 Weeks Volatility :79.41%

    Upside

    15.0%

    downward going graph

Returns

PeriodEsperion Therapeutics, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
41.46%
-0.5%
0.0%
6 Months
97.28%
9.6%
0.0%
1 Year
135.77%
11.8%
0.0%
3 Years
-88.73%
17.5%
-24.3%

Highlights

Market Capitalization
551.3M
Book Value
- $1.57
Earnings Per Share (EPS)
-0.9
PEG Ratio
-4.78
Wall Street Target Price
7.41
Profit Margin
-37.65%
Operating Margin TTM
52.47%
Return On Assets TTM
-6.94%
Return On Equity TTM
-260.79%
Revenue TTM
229.7M
Revenue Per Share TTM
1.83
Quarterly Revenue Growth YOY
466.09999999999997%
Gross Profit TTM
-70.4M
EBITDA
-34.6M
Diluted Eps TTM
-0.9
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.04
EPS Estimate Next Year
0.01
EPS Estimate Current Quarter
0.05
EPS Estimate Next Quarter
-0.21

Analyst Recommendation

Buy
    71%Buy
    28%Hold
    0
    0%Sell
Based on 14 Wall street analysts offering stock ratings for Esperion Therapeutics, Inc.(by analysts ranked 0 to 5 stars)
Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
10
Hold
4
4
4
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 156.4%

Current $2.89
Target $7.41

Company Financials

FY18Y/Y Change
Revenue
184.5M
-
Net Income
-201.8M
↑ 20.85%
Net Profit Margin
-109.4%
-
FY19Y/Y Change
Revenue
148.4M
↓ 19.57%
Net Income
-109.0M
↓ 45.98%
Net Profit Margin
-73.48%
↑ 35.92%
FY20Y/Y Change
Revenue
227.5M
↑ 53.37%
Net Income
-166.2M
↑ 52.44%
Net Profit Margin
-73.04%
↑ 0.44%
FY21Y/Y Change
Revenue
78.4M
↓ 65.52%
Net Income
-318.8M
↑ 91.84%
Net Profit Margin
-406.42%
↓ 333.38%
FY22Y/Y Change
Revenue
75.5M
↓ 3.79%
Net Income
-287.8M
↓ 9.73%
Net Profit Margin
-381.34%
↑ 25.08%
FY23Y/Y Change
Revenue
116.3M
↑ 54.14%
Net Income
-209.2M
↓ 27.3%
Net Profit Margin
-179.87%
↑ 201.47%
Q4 FY22Q/Q Change
Revenue
18.8M
↓ 0.85%
Net Income
-68.5M
↓ 0.22%
Net Profit Margin
-363.81%
↓ 2.32%
Q1 FY23Q/Q Change
Revenue
24.3M
↑ 29.29%
Net Income
-89.2M
↑ 30.32%
Net Profit Margin
-366.72%
↓ 2.91%
Q2 FY23Q/Q Change
Revenue
25.8M
↑ 5.99%
Net Income
-49.9M
↓ 44.03%
Net Profit Margin
-193.65%
↑ 173.07%
Q3 FY23Q/Q Change
Revenue
34.0M
↑ 31.73%
Net Income
-41.3M
↓ 17.39%
Net Profit Margin
-121.43%
↑ 72.22%
Q4 FY23Q/Q Change
Revenue
32.3M
↓ 5.06%
Net Income
-56.3M
↑ 36.59%
Net Profit Margin
-174.71%
↓ 53.28%
Q1 FY24Q/Q Change
Revenue
137.7M
↑ 327.09%
Net Income
61.0M
↓ 208.3%
Net Profit Margin
44.3%
↑ 219.01%
FY18Y/Y Change
Total Assets
143.5M
↓ 48.37%
Total Liabilities
64.3M
↑ 94.1%
FY19Y/Y Change
Total Assets
214.4M
↑ 49.49%
Total Liabilities
194.5M
↑ 202.33%
FY20Y/Y Change
Total Assets
353.3M
↑ 64.73%
Total Liabilities
449.4M
↑ 131.05%
FY21Y/Y Change
Total Assets
381.6M
↑ 8.02%
Total Liabilities
578.5M
↑ 28.74%
FY22Y/Y Change
Total Assets
247.9M
↓ 35.02%
Total Liabilities
571.7M
↓ 1.18%
FY23Y/Y Change
Total Assets
205.8M
↓ 17.0%
Total Liabilities
660.8M
↑ 15.58%
Q4 FY22Q/Q Change
Total Assets
247.9M
↓ 20.74%
Total Liabilities
571.7M
↓ 5.8%
Q1 FY23Q/Q Change
Total Assets
251.8M
↑ 1.56%
Total Liabilities
581.5M
↑ 1.71%
Q2 FY23Q/Q Change
Total Assets
234.6M
↓ 6.83%
Total Liabilities
606.6M
↑ 4.32%
Q3 FY23Q/Q Change
Total Assets
221.3M
↓ 5.68%
Total Liabilities
631.3M
↑ 4.07%
Q4 FY23Q/Q Change
Total Assets
205.8M
↓ 7.01%
Total Liabilities
660.8M
↑ 4.67%
Q1 FY24Q/Q Change
Total Assets
373.1M
↑ 81.28%
Total Liabilities
667.4M
↑ 0.99%
FY18Y/Y Change
Operating Cash Flow
-148.6M
↑ 13.2%
Investing Cash Flow
140.4M
↓ 491.74%
Financing Cash Flow
10.7M
↓ 93.46%
FY19Y/Y Change
Operating Cash Flow
-70.3M
↓ 52.68%
Investing Cash Flow
64.2M
↓ 54.27%
Financing Cash Flow
136.2M
↑ 1173.56%
FY20Y/Y Change
Operating Cash Flow
-85.2M
↑ 21.09%
Investing Cash Flow
21.4M
↓ 66.75%
Financing Cash Flow
201.7M
↑ 48.11%
FY21Y/Y Change
Operating Cash Flow
-263.8M
↑ 209.72%
Investing Cash Flow
-50.5M
↓ 336.39%
Financing Cash Flow
268.2M
↑ 32.96%
FY22Y/Y Change
Operating Cash Flow
-174.8M
↓ 33.73%
Investing Cash Flow
8.1M
↓ 116.05%
Financing Cash Flow
32.6M
↓ 87.84%
Q4 FY22Q/Q Change
Operating Cash Flow
-42.5M
↓ 0.84%
Investing Cash Flow
-11.8M
↓ 135.74%
Financing Cash Flow
-30.4M
↓ 165.58%
Q1 FY23Q/Q Change
Operating Cash Flow
-54.4M
↑ 27.98%
Investing Cash Flow
25.0M
↓ 311.97%
Financing Cash Flow
49.5M
↓ 263.03%
Q2 FY23Q/Q Change
Operating Cash Flow
-24.8M
↓ 54.47%
Investing Cash Flow
17.5M
↓ 30.0%
Financing Cash Flow
809.0K
↓ 98.37%

Technicals Summary

Sell

Neutral

Buy

Esperion Therapeutics, Inc. is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Esperion Therapeutics, Inc.
Esperion Therapeutics, Inc.
30.04%
97.28%
135.77%
-88.73%
-94.15%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
-2.2%
9.45%
42.42%
33.66%
59.37%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
0.85%
0.85%
2.34%
12.28%
12.28%
Zoetis Inc.
Zoetis Inc.
6.33%
-6.75%
7.85%
-3.27%
60.21%
Viatris Inc.
Viatris Inc.
-6.34%
7.8%
13.19%
-31.93%
-34.88%
Catalent, Inc.
Catalent, Inc.
0.02%
49.62%
30.46%
-49.07%
12.7%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Esperion Therapeutics, Inc.
Esperion Therapeutics, Inc.
NA
NA
-4.78
-0.04
-2.61
-0.07
NA
-1.57
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
36.18
36.18
0.44
4.07
0.18
0.1
NA
23.72
Haleon Plc Spon Ads
Haleon Plc Spon Ads
27.93
27.93
1.69
0.46
0.07
0.04
0.03
1.8
Zoetis Inc.
Zoetis Inc.
34.46
34.46
2.58
5.77
0.5
0.14
0.01
11.07
Viatris Inc.
Viatris Inc.
224.4
NA
NA
2.74
0.0
0.03
0.05
16.81
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.06
0.25
-0.28
-0.01
NA
19.96
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Esperion Therapeutics, Inc.
Esperion Therapeutics, Inc.
Buy
$551.3M
-94.15%
NA
-37.65%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$13.4B
59.37%
36.18
18.65%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$38.6B
12.28%
27.93
9.64%
Zoetis Inc.
Zoetis Inc.
Buy
$81.6B
60.21%
34.46
27.38%
Viatris Inc.
Viatris Inc.
Hold
$12.5B
-34.88%
224.4
-0.37%
Catalent, Inc.
Catalent, Inc.
Hold
$10.2B
12.7%
211.02
-28.44%

Institutional Holdings

  • Orbimed Advisors, LLC

    7.24%
  • Bellevue Group AG

    5.25%
  • Wasatch Advisors LP

    4.82%
  • Vanguard Group Inc

    4.66%
  • Great Point Partners LLC

    4.22%
  • Woodline Partners LP

    4.18%

Company Information

esperion therapeutics, inc. is a pharmaceutical company focused on developing and commercializing first-in-class, oral, ldl-c lowering therapies for the treatment of patients with hypercholesterolemia. etc-1002, the company's lead product candidate, is an inhibitor of atp citrate lyase, a well-characterized enzyme on the cholesterol biosynthesis pathway; the same pathway that includes hmg-coa reductase, the enzyme target of statins. the company has successfully completed its phase 1 and phase 2 development programs for etc-1002, and plans to initiate its etc-1002 phase 3 development program by the end of 2015. for more information, please visit www.esperion.com.

Organization
Esperion Therapeutics, Inc.
Employees
240
CEO
Mr. Sheldon L. Koenig
Industry
Health Technology

FAQs